Medpace: Research boom for obesity treatments drives growth in the metabolic disease therapy sector!

Medpace acts as a contract research organization that plans and manages clinical studies worldwide – primarily for small and medium-sized biotech companies that do not have their own capacities. In the second quarter, revenue increased by 17.2% and earnings per share (EPS) rose by 37%, significantly driven by the research boom in metabolic diseases (such as obesity). Thanks to a strong order situation, management raised the annual forecast, causing the stock to soar by 24% to a new all-time high. An external engine for drug development...